Lifeboat Foundation

While investigating how string theory can be used to explain certain physical phenomena, scientists at the Indian Institute of Science (IISc) have stumbled upon on a new series representation for the irrational number π. It provides an easier way to extract π from calculations involved in deciphering processes like the quantum scattering of high-energy particles.

Remember how difficult it was to find one Higgs boson? Try finding two at the same place at the same time. Known as di-Higgs production, this fascinating process can tell scientists about the Higgs boson self-interaction.

The so-called Casimir force or Casimir effect is a quantum mechanical phenomenon resulting from fluctuations in the electromagnetic field between two conducting or dielectric surfaces that are a short distance apart. Studies have shown that this force can be either be attractive or repulsive, depending on the dielectric and magnetic properties of the materials used in experiments.

Researchers at University of Tsukuba have developed an ultrafast time-resolved scanning electron microscopy instrument by integrating a scanning electron microscope with a femtosecond laser. This innovative system facilitates the observation of the instantaneous states of various materials. Their paper is published in the journal ACS Photonics.

Researchers at the Weizmann Institute of Science discovered a new type of vortex formed by photon interactions, which could advance quantum computing.

Vortex Phenomena

Continue reading “Vortex Power: The Swirl of Light Revolutionizing Quantum Computing” »

Johnson’s latest foray into anti-aging science took him to the Roatan, an island off the coast of Honduras, where he received follistatin gene therapy in the form of two injections. The entrepreneur says that he spent $20,000 on reversible gene therapy developed by the method development company Minicircle.

Over the past decade, immune checkpoint inhibitors (ICI) have revolutionized the cancer treatment area. These drugs block the interaction between proteins known as immune checkpoints and immune cells within our bodies. At times, immune checkpoints play a vital role in immune regulation, preventing unnecessary responses. However, tumors can upregulate proteins, thus evading an immune response, and in a tumor setting, this response is indeed necessary. ICIs interfere with checkpoint pathways and allow active immunity against cancer.

In 2011, the United States Foor and Drug Administration (FDA) approved the first ICI, ipilimumab, a CTLA-4 blocker, for treating advanced melanoma. Subsequently, ICIs targeting PD1 (pembrolizumab and nivolumab) and PDL1 (atezolizumab and durvalumab) received approval for treating various malignancies. Many clinical trials test the efficacy of novel ICIs in different settings.

A recent study published in Science Immunology unveiled a promising new avenue for cancer immunotherapy and ICIs. The study evaluated a drug targeting an immune checkpoint molecule called VISTA (V-domain immunoglobulin suppressor of T cell activation), shedding light on its potential as an effective immunotherapy target.

Researchers developed a model for reproduction at life’s origin via spontaneous selective clustering of small lipid molecules.

The cost of new gene-based sickle cell treatments isn’t the only barrier to access. Coming up with new ways to treat the whole disease—and person—could make treatment more equitable.

By Shobita Parthasarathy

Last fall, to great fanfare, US regulators approved two gene therapies for sickle cell disease, and the European Union and UK soon followed. Many people hope that these treatments will provide a “functional cure” for the genetic condition, which causes rigid, misshapen red blood cells that lead to anemia, episodes of extreme pain, blood vessel and organ damage, stroke risk and lower life expectancy. These sickle cell therapies also bring us closer to an age of “CRISPR medicine” in which new gene-editing tools could be used to fix a range of debilitating genetic diseases, including Duchenne muscular dystrophy and cancer.